Anti-cancer drugs play a pivotal role in the ongoing battle against cancer, working tirelessly at the cellular level to impede the growth and spread of malignant cells. These medications encompass a diverse array, from chemotherapy to targeted therapies, each designed to thwart the unique characteristics of cancer cells. By interfering with specific molecular processes, these drugs aim to halt the relentless progression of the disease. In recent years, ground-breaking advancements in the development of anti-cancer drugs have emerged, offering more targeted and effective treatment options.
Precision medicine, a paradigm shift in cancer therapy, tailors these drugs to the genetic makeup of individual tumors, optimizing therapeutic outcomes while minimizing side effects. Despite the challenges, ongoing research and innovation continue to redefine the landscape of anti-cancer drugs, bringing hope and resilience to those affected by this formidable adversary. As the field evolves, the quest for more potent and personalized therapies remains a driving force in the relentless pursuit of a cancer-free future.
Vladlen Slepak
University of Miami School of Medicine, United States
Axel H Schonthal
University of Southern California, United States
Bernd Blobel
University of Regensburg, Germany
Consolato M Sergi
University of Alberta, Canada
Luis Jesus Villarreal Gomez
Universidad Autónoma de Baja California, Mexico
Lan Wang
Paretor LLC, United States
Maria Cristina Gamberini
University of Modena and Reggio Emilia, Italy
Lucas Amaral Machado
University of Sao Paulo State – UNESP, Brazil
Saad Tayyab
UCSI University, Malaysia
Anil Pareek
Anand Pharmacy College, IndiaSubmit your abstract Today
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : From marker to mechanism: Ligand discovery enables functional analysis of OR51E1, an ectopic olfactory receptor, in prostate cancer
Vladlen Slepak, University of Miami School of Medicine, United States
Title : Hydrogen sulfide in sepsis: From bench to bedside
Madhav Bhatia, University of Otago, New Zealand
Title : Tailored cellular environments to enable drug design
Lan Wang, Paretor LLC, United States
Title : Development of novel drug delivery pathways enabled by perillyl alcohol (NEO100), A monoterpene with multifaceted biomedical applications
Axel H Schonthal, University of Southern California, United States
Title : A NAMs-compatible mechanopharmacological model of drug penetration in the urinary bladder
Kunal Sharma, Swisss Federal Institute of Technology Lausanne, Switzerland
Title : Application of quality by design for pulmonary liposomes: Preliminary study to nano in-microparticle
Lucas Amaral Machado, University of Sao Paulo State – UNESP, Brazil
Title : Integrated Raman, SERS and computational approaches for the study of bioactive molecules in pharmaceutical chemistry
Maria Cristina Gamberini, University of Modena and Reggio Emilia, Italy
Title : The impact of metal-decorated polymeric nanodots on proton relaxivity
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, University of Alberta, Canada